

第15回

豊橋ライブデモンストレーションコース

症例集

THE 15th
TOYOHASHI
LIVE

6.26
THU

Global Case1 80's male

Target Lesion: RCA

Diagnosis: AP

Prior intervention:
none

Coronary risk factor:
HT, DL

eGFR: 56.6

SYNTAX Score: 31

J-CTO Score: 1


High bleeding risk : Yes

Final CAG findings: Jun. 2025

Prox. RCA 100%,


Mid. LAD 100%, Mid. LCX 100%

LV EF(UCG): 54%




Global Case1 CT

Calc.+



CTO Length
:27.0mm



Global Case2 80's male

Target Lesion: Ost.LCX

Diagnosis: AP, LEAD

Prior intervention:

2008.03	PCI stent & POBA (Mid.LAD & Dis.LCX)
2012.01	EVT stent (Lt.CIA)
2013.02	PCI POBA (Mid.LAD)
2014.08	PCI DCB (Mid.LAD)
2020.06	EVT DCB (Rt,SFA)
2025.04	PCI stent (Prox.RCA)
2025.05	PCI DCB (Mid.LAD ISR)

Coronary risk factor:

DM, HT, FH, Past smoking

eGFR: 61.7

SYNTAX Score: 19

High bleeding risk : Yes

Final CAG findings: 2025.03



Ost.LCX 75%

Mid.LAD 75% → 0% (DCB)


Prox.RCA 90% → 0% (stent)

LV EF(UCG): 58.4%

FFR: LCX RFR:0.86, FFR:0.78



Global Case2 CT



PCI Case4 70's male

Target Lesion: Prox. LAD

Diagnosis: AP, OMI, CKD

Prior intervention:

2024.05 PCI Stent (Mid. LAD)

Coronary risk factor:

DM, HT, DL, FH

eGFR: 31.5

SYNTAX Score: 14

High bleeding risk : Yes

Final CAG findings: 2025.06


Prox. LAD 75%,

Mid. LAD 90% → 0%(PCI)

LV EF(UCG): 59.7%

MRI: Anterior, Antero-septal,lateral ischemia(+)

FFR: LAD iFR 0.63, FFR 0.79



Amulet (左心耳閉鎖術) Live Demonstration

症例:80代, 男性

既往:

- ✓ 高血圧
- ✓ 脂質異常症
- ✓ 狭心症
- ✓ 慢性腎不全
- ✓ 慢性心房細動
- ✓ 陳旧性ラクナ梗塞、microbleeds (+)
- ✓ 脳出血
- ✓ 多発性胃潰瘍(黒色便)

CHA₂DS₂VASc : 6

HAS-BLED : 4

現病歴:

- ✓ 慢性心房細動で脳幹梗塞・多発性胃潰瘍で黒色便の既往がありLAACを予定した


内服:

エドキサバン60mg, カルベジロール10mg, エソメプラゾール20mg, フェブキソスタット20mg,
ロスバスタチン2.5mg, アムロジピン5mg

採血

AST	20 IU/l
ALT	16 IU/l
BUN	35.4 mg/dl
Cre	1.88 mg/dl
eGFR	27.3
UA	5.1 mg/dl
Na	140.5 mEq/l
K	4.7 mEq/l
BNP	82.2 pg/ml
HbA1c	5.7 %
WBC	7070 μ l
Hb	11.4 g/dl


胸部レントゲン





心臓超音波検査




12誘導心電図




術前造影CT



3D view



TEE view




	0 deg	45 deg	90 deg	135 deg
LAA ostium, mm	31.1	29.5	25.9	28.7
LAA landing, mm	24.5	24.7	25.3	25.2

	0 deg	45 deg	90 deg	135 deg
LAA ostium, mm	31.1	29.5	25.9	28.7
LAA landing, mm	24.5	24.7	25.3	25.2

IMAGING AND SIZING

Device Selection



MAXIMUM LANDING ZONE WIDTH (mm)	AMULET™ DEVICE SIZE	LOBE LENGTH (mm)	MINIMUM LAA DEPTH (mm)	DISC DIAMETER (mm)	SHEATH DIAMETER
11.0 - 13.0	16	7.5	≥10	22	12 F or 14 F (with adaptor)
13.0 - 15.0	18	7.5	≥10	24	
15.0 - 17.0	20	7.5	≥10	26	
17.0 - 19.0	22	7.5	≥10	28	
19.0 - 22.0	25	10	≥12	32	
22.0 - 25.0	28	10	≥12	35	14 F
25.0 - 28.0	31	10	≥12	38	
28.0 - 31.0	34	10	≥12	41	

WATCHMAN FLX Pro (左心耳閉鎖術) Live Demonstration

症例:70代, 男性

既往:

- ✓ 狭心症 (2024 PCI)
- ✓ 下肢動脈閉塞性硬化症 (EVT)
- ✓ 慢性腎不全 (PD)
- ✓ 糖尿病 (II型)
- ✓ 脂質異常症
- ✓ 食道裂孔ヘルニア
- ✓ 十二指腸潰瘍
- ✓ 二次性副甲状腺機能亢進症
- ✓ 高リン血症
- ✓ 高血圧症
- ✓ 鉄欠乏状態
- ✓ 低亜鉛血症
- ✓ 発作性心房細動
- ✓ 下肢静脈血栓症
- ✓ 脳動脈瘤
- ✓ 貧血 (Hb7.8g/dl→他院にて輸血, 注射繰り返す)

CHA₂DS₂-VASc : 5

HAS-BLED : 6

現病歴:

- ✓ 腹膜透析、DM、狭心症/下肢動脈治療歴あり。PAFもあり、アブレーションを考慮していたが、INRがなかなか至適範囲内に治まらず、さらにINR<1.6ではあるが貧血も進行していたため、LAACを先行し貧血を改善させてから改めてアブレーションを考える方針とした。


内服:

ワルファリン1mg、クロピドグレル75mg、クエン酸第一鉄トリウム100mg、ロバスタチン5mg、トラゼンタ20mg、エソメプラゾール20mg、シルニジピン10mg、フェブリク10mg、アルファカルシドール0.5 μg、スピノロラクトン25mg、トリクロルメチアジド1mg、センノシド24mg、エロピキシバット15mg、エボカルセト1mg

採血

AST	19 IU/l
ALT	17 IU/l
BUN	35.6 mg/dl
Cre	9.25 mg/dl
eGFR	4.9
UA	3.0 mg/dl
Na	138.9 mEq/l
K	4.2 mEq/l
BNP	113 pg/ml
HbA1c	6.3 %
WBC	4190 μ l
Hb	10.7 g/dl


胸部レントゲン





心臓超音波検査




12誘導心電図




術前造影CT



3D view




TEE view



	0 deg	45 deg	90 deg	135 deg
Diameter, mm	23.3	16.9	14.8	21.4
Depth, mm	18.9	19.1	14.2	25.3

	0 deg	45 deg	90 deg	135 deg
Diameter, mm	23.3	16.9	14.8	21.4
Depth, mm	18.9	19.1	14.2	25.3

最大径の範囲 (mm)	デバイス長 (圧縮率10-30%)	デバイスのサイズ (mm)
14.0 - 18.0	14 - 18	20
16.8 - 21.6	14 - 19	24
18.9 - 24.3	15 - 20	27
21.7 - 27.9	16 - 23	31
24.5 - 31.5	18 - 26	35
28.0 - 36.0	21 - 30	40



THE 15th
TOYOHASHI
LIVE

6.27
FRI

PCI Case10 80's female

Target Lesion: LMT bifurcation & mid.LAD

Diagnosis: AP, CKD

Prior intervention:

2025.05 PMI

Coronary risk factor:

DM, HT

eGFR: 26.5

SYNTAX Score: 26

High bleeding risk : Yes

Final CAG findings: 2025.05

LMT bifurcation 90%, Mid.LAD 75%

PD branch 90%




LV EF(UCG): 67.2%

FFR: LAD iFR 0.64, FFR 0.69

LCX iFR 0.94, FFR:0.91



Global Case10 CT



PCI Case2 60's male

Target Lesion: LMT

Diagnosis: AP

Prior intervention:

none

Coronary risk factor:

DL, HT

eGFR: 68.1

SYNTAX Score: 14

High bleeding risk : No



Final CAG findings: 2025.06

LMT 75%



Diagonal branch 75%

LV EF(UCG): 60%

FFR: LMT-LAD iFR 0.76, FFR:0.61



PCI Case2 CT



PCI Case3 70's male

Target Lesion: Ost.LCX

Diagnosis: AP, OMI

Prior intervention:

2025.04 PCI Stent (Mid. LAD)

Coronary risk factor:

HT

eGFR: 59.2

SYNTAX Score: 14

High bleeding risk : No

Final CAG findings: 2025.03


Ost. LCX 90-99%,

Mid. LCX 90%


Prox.LAD 75% → 0%(PCI)

LV EF(UCG): 47.3%

MRI: Anterior, Antero-septal → LAD PCI
Infero-lateral ischemia(+)



PCI Case3 CT



THE 15th
TOYOHASHI
LIVE

6.28
SAT

PCI Case5 80's female

Target Lesion: RCA

Diagnosis: AP, LEAD, CKD, AF

Prior intervention:

- | | |
|---------|--|
| 2016.06 | PCI Stent (LMT-prox. LAD)
PCI POBA (mid. LCX) |
| 2017.10 | PCI POBA (prox.-mid. LCX reste.)
EVT Stent (Ao-Bilat.CIA) |

Coronary risk factor:

HT, DL, Family history, current smoking

eGFR: 27.3

SYNTAX Score: 40.5

High bleeding risk : Yes

Final CAG findings: 2025.05


Ost. RCA 90%, Mid. RCA 100%,

Mid. LAD 90% →0%(DCB), Ost. Diagonal 90%,


Prox.-Mid. LCX 75%, OM 100%

LV EF(UCG): 47%




MRI: Inferior, Infero-septal, Infero-lateral: ischemia(+)



PCI Case5 CT



Calcium Score:2388



PCI Case6 70's male

Target Lesion: LMT

Diagnosis: AP, OMI

Prior intervention:

2010.09 TAR, CABG (Ao-SVG-#4PD-#14)

2017.01 AAAR

Coronary risk factor:

DM, HT, DL

eGFR: 62.5

SYNTAX Score: 13

High bleeding risk : No



Final CAG findings: 2025.06

LMT 90%


CABG: Ao-SVG-#4PD-#14:patent

LV EF(UCG): 66.0%

MRI: Anterior, Antero-septal,lateral ischemia(+)




PCI Case6 CT






MLD

5.2x4.9mm



Calcium
CT number
1780(±20)HU



PCI Case7 70's male

Target Lesion: Prox.-mid LAD

Diagnosis: AP

Prior intervention:

2025.05 PCI DCB (Dis. RCA)

2025.06 PCI DCB (Prox.LCX)

Coronary risk factor:

HT

eGFR: 47.1

SYNTAX Score: 27

High bleeding risk : Yes


Final CAG findings: 2025.05

Prox.-mid LAD 75-90%,





Dis. RCA 99% → 25% (DCB)

Prox. LCX 90% → 25% (DCB)

LV EF(UCG): 59.3%





PCI Case7 CT



Calcium
CT number
1450(±30)HU

#6

3.6x3.5mm



PCI Case8 80's male

Target Lesion: LMT bifurcation

Diagnosis: AP

Prior intervention:

2018.05 PCI stent (Dis. RCA)

2024.08 PCI DCB (Ost.LCX)

Coronary risk factor:

DM, DL, HT, FH

eGFR: 59.6

SYNTAX Score: 23

High bleeding risk : Yes


Final CAG findings: 2025.06

LMT bifurcation 90% (Medina: 1-1-1)



Dis.LCX 75%

LV EF(UCG): 66.0%

MRI: Anterior, Antero-septal,lateral ischemia(+)



PCI Case8 CT



PCI Case1 70's male

Target Lesion: RCA

Diagnosis: AP, Post TAVI

Prior intervention:

2025.05 TAVI(Sapien3 UR26mm)
by other hospital

Coronary risk factor:

DL, past smoking

eGFR: 66.8

SYNTAX Score: 33

High bleeding risk : No

Final CAG findings: 2025.04 (other hospital)


Prox.-mid & dis.RCA 75-90%

LMT-prox.LAD 75-90%




Prox.-mid LCX 75-90%

Diagonal branch 75%

LV EF(UCG): 56%



PCI Case1 CT



EVT Case1 70's male

Target Lesion: *Rt.SFA restenosis*

Diagnosis: LEAD

ABI: R=0.78, L=0.94

Rutherford: 3

Prior intervention:

2000-2023 PCI × 10

2024.01 EVT stent (Lt,SFA)

2024.05 PCI DCB (Prox.RCA)

2024.06 EVT DCB (Prox. & Mid.SFA)


Risk factor:

DM, HT, DL

eGFR: 47.4



Final Angio findings: 2025.05

Rt: SFA 90%







EVT Case1 CT



diffuse calc.



Calc.

EVT Case2 60's male

Target Lesion: Lt.CIA CTO

Diagnosis: LEAD

ABI: R=1.10, L=0.66

Rutherford: 3

Prior intervention:

none


Risk factor:

DM, HT, DL, past smoking

eGFR: 69.6

Final CT findings: 2025.06

Lt: CIA 100%



EVT Case3 70's male

Target Lesion: Lt.SFA

Diagnosis: LEAD

ABI: R=0.55, L=0.56

Rutherford: 3

Prior intervention:

2025.04 EVT stent (Lt,CIA-EIA)

Risk factor:

DM, HT, DL

eGFR: 77.8



Final Angio findings: 2025.04

Lt: SFA 100%




EVT Case3 CT

CT number
62(±8.0)HU
Thrombus+



**CTO Length
:233mm**





EVT Case4 70's male

Target Lesion: Rt.SFA

Diagnosis: LEAD

ABI: R=0.58, L=0.49

Rutherford: 2

Prior intervention:

none

Risk factor:

DM, Past smoking

eGFR: 72.6

Final Angio findings: 2025.05



Rt: SFA 100%

Lt: EIA 90%, CFA 100%



EVT Case4 CT

CT number
63(±8)HU
Thrombus+



EVT Case6 90's male

Target Lesion: Lt.CIA

Diagnosis: LEAD, CRF on HD

ABI: R=0.95, L=0.75

Rutherford: 3

Prior intervention:

none

Risk factor:


DM, Past smoking

eGFR: 5.6

Final Angio findings: 2025.01

Lt: EIA 90%

Rt: EIA 75%



TAVI case presentation


**[Nagoya Heart Center]
[6.28 2025]**

Case 1 70's male


- **Diagnosis:**
Severe AS (Bicuspid Valve)
- **Clinical Symptoms:**
Dyspnea on effort
(NYHA functional class II)
- **Past Medical History:**
Stroke
- **Risk score:**
STS 0.83%, Euro2 score 1.12%

Live Demonstration SHD_TAVI in Nagoya

XP



ECG



Labo

Hb 14.0g/dl, Cre 0.80mg/dl, eGFR 72.0




Live Demonstration SHD_TAVI in Nagoya

UCG

[A valve]


AR trivial PHT ms
 AS severe
 AVA(planimetry法) 0.75 cm² P-PG 82.0 mmHg
 AVA(連続の式) 0.43 cm² m-PG 47.0 mmHg
 AVA Index 0.2 PV 4.52 m/s

【Dimension】		正常値	今回
IVSd	mm	7~11	11.5
LVPWd	mm	7~11	11.2
LVDd	mm	38~53	51.1
LVDs	mm	20~35	39.7
EF(Teich)	%	55~85	44.7
EF(Mod)	%	55~85	46.6
FS	%		22.3
HR	bpm		51.0
CO	L/min		2.8




Live Demonstration SHD_TAVI in Nagoya


AV sizing



Annulus
Area: 528.8mm²
Perimeter: 84.2mm



Valsalva
32.6 * 33.7 * 37.7mm




STJ
30.9 * 28.1mm



Live Demonstration SHD_TAVI in Nagoya


AV sizing




Coronary height

RCA 15.8mm


LCA 15.4mm



Commissure line 28.2mm



Ca Score 2862





membranous septum

1.3mm



Live Demonstration SHD_TAVI in Nagoya

Coronary Artery





Coronary no significant stenosis



Live Demonstration SHD_TAVI in Nagoya

Access Route




Case 2 80's female

- **Diagnosis:**
Severe AS
- **Clinical Symptoms:**
AP, Dyspnea on effort
(NYHA functional class II)
- **Past Medical History:**
HT, HL, DM,
- **Risk score:**
STS 9.77%, Euro2 score 3.08%




Live Demonstration SHD_TAVI in Nagoya

XP



ECG



Labo

Hb 14.4g/dl, Cre 0.86mg/dl, eGFR 47.0



Live Demonstration SHD_TAVI in Nagoya

UCG

【rhythm】	sinus		
【Dimension】	正常値	今回	
IVSd	mm	7~11	11.5
LVPWd	mm	7~11	11.1
LVDd	mm	34~48	36.1
LVDs	mm	18~30	23.8
EF(Teich)	%	59~88	64.7
EF(Mod)	%	59~88	61.1

【A valve】


AR trivial PHT ms
 AS severe

AVA(planimetry法) 0.77 cm² P-PG 78.0 mmHg
 AVA(連続の式) 0.91 cm² m-PG 42.0 mmHg
 AVA Index 0.6 PV 4.43 m/s

三尖 三尖とも石灰化、可動性は弁先端側のみ。
 流速は上行Ao側から計測。
 目視・計測ともにsevere AS。上行Ao拡大


【大動脈径】

弁輪径 mm STJ 24.2 mm
 Valsalva径 29.5 mm 上行大動脈 38.0 mm




Live Demonstration SHD_TAVI in Nagoya


AV sizing



Annulus
Area: 333.5mm²
Perimeter: 67.0mm



Valsalva
28.8 * 27.1 * 26.4mm



STJ
23.7 * 22.1mm




Live Demonstration SHD_TAVI in Nagoya


AV Sizing




Coronary ostium




F



Ca Score 1822




membranous septum
1.8mm



RCA 14.5mm

Coronary height




LCA 10.9mm



Live Demonstration SHD_TAVI in Nagoya

Coronary Artery






#1 50%, #2 50%, #3 50%, #4 90%, #6 90%, #7 90%,



Live Demonstration SHD_TAVI in Nagoya

Access Route



Ascending-Descending View 15°




Case 3 80's female

- **Diagnosis:**
Severe AS
- **Clinical Symptoms:**
Dyspnea on effort
(NYHA functional class II)
- **Past Medical History:**
卵巣癌, 腹膜播腫(予後1年程度見込める)
- **Risk score:**
STS 4.16%, EuroSCORE II 1.74%




Live Demonstration SHD_TAVI in Nagoya

XP



ECG



Labo


Hb 8.3g/dl, Cre 0.5mg/dl, eGFR 83.0




Live Demonstration SHD_TAVI in Nagoya

UCG


Aortic Valve		
Vel max	3.21	m/s
PG max	41.3	mmHg
PG mean	28.6	mmHg
AVA(CW)	0.83	cm ²
AVA(2D)	1.48	cm ²
PHT(AR)		ms
Dimension & volume		
AOD	27.2	mm
LAD	47.7	mm
LVDd	43.2	mm
LVDs	28.0	mm
IVS	8.5	mm
LVPW	8.8	mm
EDV	83.8	ml
ESV	29.7	ml
EF		
Bモード法	64.6	%




AV sizing



Annulus
Area: 337.6mm²
Perimeter: 68.5mm





Valsalva
23.6 * 25.3 * 24.5mm



STJ
22.6 * 20.2mm



Live Demonstration SHD_TAVI in Nagoya

AV Sizing



RCA 12.4mm


LCA 10.2mm



membranous
septum 2.9mm




Coronary Artery



Coronary no significant stenosis

Live Demonstration SHD_TAVI in Nagoya

Access Route




Case 4 80's female


- **Diagnosis:**
Severe AS
- **Clinical Symptoms:**
Dyspnea on effort
(NYHA functional class II)
- **Past Medical History:**
HTN, Dyslipidemia, Cerebral infarction (2009)
- **Risk score:**
STS 4.62%, EuroSCORE II 2.38%

Live Demonstration SHD_TAVI in Nagoya

XP



ECG



Labo

Hb 12.1g/dl, Cre 0.8mg/dl, eGFR 51.1



Live Demonstration SHD_TAVI in Nagoya

UCG

[rhythm]	sinus		
[Dimension]	正常値	今回	
IVSd	mm	7~11	11.3
LVPWd	mm	7~11	10.8
LVDd	mm	34~48	50.0
LVDs	mm	18~30	33.5
EF(Teich)	%	59~86	61.3
EF(Mod)	%	59~86	
FS	%		33.0
HR	bpm		62.0
CO	L/min		4.0
SV	ml		64.0
LVMass	g		208.0
AOD	mm	25~36	26.4
LAD	mm	23~41	43.6

[A valve]


AR mild PHT 472.0 ms
 AS severe

AVA(planimetry法) 0.60 cm² P-PG 73.0 mmHg
 AVA(連続の式) 0.69 cm² m-PG 40.0 mmHg
 AVA Index 0.5 PV 4.26 m/s

三尖とも石灰化(+) 特にRCCは石灰化強く可動性乏しい
 NCC・LCCも可動性低下 目視・計測値よりAS severe
 ARは弁中央から吹きmild


[大動脈径]

弁輪径 14.1 mm STJ 26.4 mm
 Valsalva径 29.2 mm 上行大動脈 39.1 mm




Live Demonstration SHD_TAVI in Nagoya


AV sizing



Annulus
Area: 342.0mm²
Perimeter: 67.6mm



Valsalva
30.4 * 30.9 * 28.2mm




STJ
29.4 * 28.6mm




Live Demonstration SHD_TAVI in Nagoya

AV Sizing




Coronary ostium




Coronary height

RCA 10.5mm

LCA 13.4mm



Ca. score 2195






membranous septum 1.8 mm




Live Demonstration SHD_TAVI in Nagoya

Coronary Artery




Live Demonstration SHD_TAVI in Nagoya

Access Route



Live Demonstration SHD_TAVI in Nagoya

Thoracic aorta



Live Demonstration SHD_TAVI in Nagoya

Carotid Echo

